Target intelligence / Profile preview

Glutamate ionotropic receptor AMPA type subunit 4 (GluA4)

Target
GluA4
Molecular classification
Ion channel, Receptor, Ligand-gated ion channel, Ionotropic glutamate receptor
01

Overview

Glutamate ionotropic receptor AMPA type subunit 4 (GluA4; encoded by the GRIA4 gene) is a protein subunit of the AMPA receptor, a ligand-gated ion channel mediating the majority of fast excitatory synaptic transmission in the central nervous system[1][3][7][9]. The AMPA receptor is a tetramer composed of GluA1-4 subunits (encoded by GRIA1-4), and it is primarily permeable to sodium and (in some subunit combinations) calcium ions upon binding glutamate[3][1]. GluA4 is involved in synaptic plasticity, including long-term potentiation, and plays an essential role in normal CNS development, learning, and memory[1][4][3]. Dysregulation or mutation of GRIA4 is associated with neurodevelopmental disorders, intellectual disability, and possibly schizophrenia[1][7]. Drugs targeting AMPA receptors (such as perampanel) are used clinically as anticonvulsants and are in experimental use for various neurologic and psychiatric conditions.

Other names
GluA4Glutamate receptor 4GRIA4Glutamate receptor ionotropic, AMPA 4
02

Mechanism of action

Antagonism of the AMPA receptor blocks the fast excitatory synaptic transmission mediated by glutamate; Inhibition of ion channel activity (inhibits sodium and calcium influx)

03

Biological functions

Fast excitatory synaptic transmissionSignal transductionSynaptic plasticity (long-term potentiation and depression)Excitatory neurotransmission
04

Disease associations

Neurodevelopmental disorder with or without seizures and gait abnormalitiesIntellectual disability (non-specific syndromic form)Schizophrenia (identified in some haplotypes)Neuropsychiatric and neurodevelopmental disorders
05

Safety considerations

CNS depression (e.g., ataxia, somnolence)Seizure risk with antagonistsCognitive impairment (from altering glutamatergic neurotransmission)Psychiatric side effects (irritability, aggression with some antagonists)Potential for neurotoxicity with excessive modulation
06

Interacting drugs

Perampanel (selective, non-competitive antagonist)

3 more in the full profile.

07

Biomarkers

None currently in regular clinical use for patient selection or efficacy monitoringPotential: changes in AMPA receptor expression may be explored as biomarkers in neurological disease research settings

Beyond the preview

Go deeper on Glutamate ionotropic receptor AMPA type subunit 4 (GluA4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate ionotropic receptor AMPA type subunit 4 (GluA4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call